← All specialties

Outpatient & home infusion

Rheumatology, GI, neurology and ID/OPAT infusion referrals

For infusion center operators and home infusion liaisons: find the rheumatologists, gastroenterologists, neurologists and infectious disease physicians billing infused biologics and IV therapies, by city or state, then save, export and route your calls.

State dashboard

Medicare Part B infusion administration and infused drugs, latest CMS year, read live from data.cms.gov.

States with Medicare data
52 of 52
Estimated Medicare payment (national)
$2,453,266,763
Billing codes tracked
15
StateEstimated Medicare paymentServicesBilling providers (largest code)
Florida
$277,392,773
13,555,2451,926
Texas
$210,816,640
9,651,5332,125
California
$181,793,787
8,981,1682,281
New York
$117,054,131
5,594,5271,605
North Carolina
$112,785,330
6,439,772926
Illinois
$102,669,996
4,680,203903
Pennsylvania
$96,752,005
5,870,579755
South Carolina
$79,051,484
3,936,943372
Tennessee
$76,008,946
3,373,979737
Maryland
$75,247,163
3,791,009564
Virginia
$74,503,350
4,294,057557
New Jersey
$70,643,278
3,947,336678
Arizona
$66,082,886
3,888,697551
Ohio
$63,844,652
3,166,650533
Georgia
$57,645,643
3,078,432624
Alabama
$54,069,089
2,216,797424
Minnesota
$51,242,874
2,615,443643
Michigan
$48,157,651
2,369,505451
Missouri
$45,946,789
2,497,538480
Colorado
$44,639,703
2,469,009424
Oklahoma
$41,443,556
2,468,852211
Indiana
$37,519,754
1,938,267351
Washington
$34,437,593
2,069,009531
Arkansas
$30,086,081
1,431,854213
Massachusetts
$29,734,288
1,683,203471
Kentucky
$25,836,629
1,535,298190
Oregon
$25,563,272
1,494,175304
Wisconsin
$25,470,961
1,410,012352
Kansas
$24,921,211
1,335,578171
Iowa
$22,894,426
1,422,027212
Louisiana
$22,438,128
1,404,337280
Nebraska
$21,113,196
1,157,809232
Mississippi
$20,788,721
1,172,004210
Connecticut
$20,240,329
1,044,816228
Utah
$19,679,427
1,261,342284
Delaware
$15,142,118
806,89960
Nevada
$14,657,130
600,930224
Idaho
$11,573,260
778,55375
New Mexico
$10,697,199
529,015128
Maine
$7,763,004
509,52771
Alaska
$6,390,224
316,352107
New Hampshire
$6,305,433
327,43151
South Dakota
$5,470,726
347,03382
Montana
$4,427,489
374,48772
District of Columbia
$4,413,667
246,188106
Rhode Island
$4,350,333
248,20855
Wyoming
$3,915,792
188,11754
Vermont
$1,898,593
74,05210
North Dakota
$1,871,908
130,51265
West Virginia
$1,683,751
83,35830
Hawaii
$1,647,232
47,56131
Puerto Rico
$1,622,011
77,30874

Top codes nationally

CodeDescriptionProvidersBeneficiariesMedicare payment
J0129Injection, abatacept, 10 mg (code may be used for medicare when drug a4,25225,596$554,799,816
J3380Injection, vedolizumab, intravenous, 1 mg5,59211,319$334,780,924
J3262Injection, tocilizumab, 1 mg3,70914,162$263,325,890
J1569Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g.3,7999,296$211,887,800
J1745Injection, infliximab, excludes biosimilar, 10 mg7,43727,763$211,838,920
J2350Injection, ocrelizumab, 1 mg1,9035,160$209,956,305
J9312Injection, rituximab, 10 mg4,13512,326$197,370,957
96413Administration of chemotherapy into vein, 1 hour or less15,007246,059$167,700,947
J1300Injection, eculizumab, 10 mg638344$101,338,806
96365Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or 23,128333,276$65,251,010
J2323Injection, natalizumab, 1 mg1,2431,501$58,768,027
J1459Injection, immune globulin (privigen), intravenous, non-lyophilized (e1,2731,662$50,207,648
96415Administration of chemotherapy into vein, each additional hour12,428101,035$13,674,994
96366Infusion into a vein for therapy, prevention, or diagnosis, each addit10,71161,080$9,712,441
Q5103Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg1,2271,265$2,652,278

“—” means CMS published no unsuppressed figure, not zero. Payment = CMS average Medicare payment × services. Original Medicare only; Medicare Advantage, Medicaid and commercial patients are not included.

Prescriber pathways show who bills infused drugs to Medicare, not who refers to your site. Drug amounts are per billing unit and are never compared across drugs. Facility, home infusion (DME/Part D), Medicare Advantage and commercial claims are outside this file. ID/OPAT prospect lists are useful, but most home IV antibiotics are billed outside Medicare Part B, so the Medicare dollar figures understate that market.